The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer
Until recently, systemic therapy for gastrointestinal malignancies was restricted to relatively noncancer-specific cytotoxic chemotherapy. Over the last 15 years targeted therapies have become available, most notably bevacizumab in the case of advanced colorectal cancer. Unfortunately, there are no...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2014-01-01
|
Series: | Journal of Carcinogenesis |
Subjects: | |
Online Access: | http://www.carcinogenesis.com/article.asp?issn=1477-3163;year=2014;volume=13;issue=1;spage=13;epage=13;aulast=Desautels |
id |
doaj-a7cf901abf454a0685d5bbdcf6fcf69f |
---|---|
record_format |
Article |
spelling |
doaj-a7cf901abf454a0685d5bbdcf6fcf69f2020-11-24T22:05:51ZengWolters Kluwer Medknow PublicationsJournal of Carcinogenesis1477-31632014-01-01131131310.4103/1477-3163.145609The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancerDanielle DesautelsCraig HarlosPiotr CzaykowskiUntil recently, systemic therapy for gastrointestinal malignancies was restricted to relatively noncancer-specific cytotoxic chemotherapy. Over the last 15 years targeted therapies have become available, most notably bevacizumab in the case of advanced colorectal cancer. Unfortunately, there are no predictive biomarkers to guide the use of this agent. In this review article, we describe the advent of "Precision Medicine" (in part, the use of patient-specific molecular markers to inform treatment) in gastrointestinal cancers: The use of monoclonal antibodies targeting epidermal growth factor receptor in advanced colorectal cancer, and human epidermal growth factor receptor 2-neu in advanced esophagogastric cancer. In both instances, biomarkers help in selecting appropriate patients for such treatment.http://www.carcinogenesis.com/article.asp?issn=1477-3163;year=2014;volume=13;issue=1;spage=13;epage=13;aulast=DesautelsColorectal canceresophagogastric cancerprecision therapytargeted therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Danielle Desautels Craig Harlos Piotr Czaykowski |
spellingShingle |
Danielle Desautels Craig Harlos Piotr Czaykowski The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer Journal of Carcinogenesis Colorectal cancer esophagogastric cancer precision therapy targeted therapy |
author_facet |
Danielle Desautels Craig Harlos Piotr Czaykowski |
author_sort |
Danielle Desautels |
title |
The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer |
title_short |
The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer |
title_full |
The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer |
title_fullStr |
The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer |
title_full_unstemmed |
The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer |
title_sort |
advent of precision therapy in gastrointestinal malignancies: targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer |
publisher |
Wolters Kluwer Medknow Publications |
series |
Journal of Carcinogenesis |
issn |
1477-3163 |
publishDate |
2014-01-01 |
description |
Until recently, systemic therapy for gastrointestinal malignancies was restricted to relatively noncancer-specific cytotoxic chemotherapy. Over the last 15 years targeted therapies have become available, most notably bevacizumab in the case of advanced colorectal cancer. Unfortunately, there are no predictive biomarkers to guide the use of this agent. In this review article, we describe the advent of "Precision Medicine" (in part, the use of patient-specific molecular markers to inform treatment) in gastrointestinal cancers: The use of monoclonal antibodies targeting epidermal growth factor receptor in advanced colorectal cancer, and human epidermal growth factor receptor 2-neu in advanced esophagogastric cancer. In both instances, biomarkers help in selecting appropriate patients for such treatment. |
topic |
Colorectal cancer esophagogastric cancer precision therapy targeted therapy |
url |
http://www.carcinogenesis.com/article.asp?issn=1477-3163;year=2014;volume=13;issue=1;spage=13;epage=13;aulast=Desautels |
work_keys_str_mv |
AT danielledesautels theadventofprecisiontherapyingastrointestinalmalignanciestargetingthehumanepidermalgrowthfactorreceptorfamilyincolorectalandesophagogastriccancer AT craigharlos theadventofprecisiontherapyingastrointestinalmalignanciestargetingthehumanepidermalgrowthfactorreceptorfamilyincolorectalandesophagogastriccancer AT piotrczaykowski theadventofprecisiontherapyingastrointestinalmalignanciestargetingthehumanepidermalgrowthfactorreceptorfamilyincolorectalandesophagogastriccancer AT danielledesautels adventofprecisiontherapyingastrointestinalmalignanciestargetingthehumanepidermalgrowthfactorreceptorfamilyincolorectalandesophagogastriccancer AT craigharlos adventofprecisiontherapyingastrointestinalmalignanciestargetingthehumanepidermalgrowthfactorreceptorfamilyincolorectalandesophagogastriccancer AT piotrczaykowski adventofprecisiontherapyingastrointestinalmalignanciestargetingthehumanepidermalgrowthfactorreceptorfamilyincolorectalandesophagogastriccancer |
_version_ |
1725824396496470016 |